@MPGPDX on twitter
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Spent hours looking and I have found one similar product to what ALR Tech is going to offer the market. The difference being that companies product is based off a Dr's own formula for dosing guidelines where as ALRT is based off dosing guidelines that are standard. ALRT platform appears to be the most adaptable to be able to change to different geographies
This means ALRT will also not have the liability of being outside dosing guidelines ever. A company that uses a self based (developed) formula may face a lot of potential liability getting to market. I find this to be pretty big as it makes the market wide open for ALRT to attack with basically zero competition. This is all patent pending as well for ALRT. I think this is a sleeping giant waiting to be unveiled. A little bit of a race as both companies seem to be in the same stage or pretty close but radically different in the software code I think is how I would put it
Clinics and DR's are just to overwhelmed these days. Go to any waiting room. Technology is going to advance how we care for chronic paitients worldwide where it makes sense. This platform makes total sense. I keep trying to find the pitfalls to blow it up but the arguments against this tool are pretty weak as I see it right now
Will open at .40 when recapitalized. From there go up fast from filings and inside look at Spectrum King. It's going to run post merger. Anything under .015 is a gift pre merger. Any buys and MM's will run it up assp
BANJ reverse with Spectrum King LED dueto close this week. Low float everyone asleep on it
As I understand there is a delay in dose adjustment today.
It's IDA for Insulin Dose Adjustment. They can help the medical provider make quick adjustments and the patient gets immediate feedback with the monitoring. It benefits all involved. I have only found two other companies that have anything remotely close to what ALRT does. It has been a much needed advancement for a long time for those with diabetes. It will equate to better care and outcomes for the patient. Big pharma will sell more product and governments and insurance companies will adopt due to the cost savings and catching issues earlier. Patients also adhere to plans better with monitoring
From February 2015 As they were applying for FDA clearance. There is one piece in here that seems pretty significant to me. I think this statement in bold will play a large role inside and outside the US. Getting adoption is the key to any disruptive system
ALR Technologies Seeks FDA Approval For Insulin Dose Adjustment Feature For Better Diabetes Management
ALRT’s Algorithm Helps Physicians Optimize Treatment And Avoid Complications
ALR Technologies Inc., a leading remote chronic care management and medical device company, is pleased to announce the submission of a 510(k) application to the U.S. Food and Drug Administration (FDA) for an innovative new addition to the Health-e-Connect system that will help busy physicians avoid common insulin dosing errors and remotely manage large populations of patients with diabetes without sacrificing the quality of care.
A first-in-class technology, the Insulin Dose Adjustment Consultation (IDAC) feature from ALRT uses an algorithm -- based on the guidelines of the American Association of Clinical Endocrinologists (AACE) -- to advise doctors instantly on the proper dose of insulin for each patient. The algorithm takes into account the current insulin dosage, the patient’s height and weight, and a review of blood glucose data from the patient’s glucose meter to efficiently deliver accurate dosing recommendations. With FDA 510(k) clearance, IDAC will become an important addition to the Health-e-Connect remote diabetes care management system.
On January 1, 2015, Medicare began reimbursing doctors for remote chronic care management practices, such as those enabled by the Health-e-Connect system. ALRT is actively negotiating with healthcare providers to capitalize on this new reimbursement while improving the quality of patient care.
“The proper dosing of insulin is one of the most important challenges in the clinical practice of diabetes,” said Bill Smith, President of ALR Technologies.
“According to the Institute for Safe Medication Practices (ISMP), insulin accounts for more than 10% of all drug dosing mistakes. Health-e-Connect with IDAC is an easy way for a prescribing clinician to optimize a patient’s insulin dose without an office visit while avoiding common errors.”
“We expect the IDAC feature will encourage the widespread adoption of intensive blood glucose management,” said Sidney Chan, Chief Executive Officer and Chairman of ALRT. “Research shows that intensive management can avoid significant micro-vascular complications and comorbidities resulting from poor blood glucose control. Besides these serious health consequences for patients, the poor outcomes produced by improper insulin dosing lead to significant, unnecessary healthcare costs.”
About ALR Technologies Inc.
ALR Technologies is a medical device company providing remote monitoring and care facilitation for patients with chronic diseases. ALRT has developed the FDA-cleared and HIPAA compliant Health-e-Connect System that collects data from blood glucose meters and uploads to a secure website. Trained Facilitators use the System to effect efficiency of care among patients, clinicians and caregivers to improve outcomes and assist health plans to optimize their quality goals. Currently, the Company is focused on diabetes and will expand its services to cover other chronic diseases anchored on verifiable data. For more information, visit www.alrt.com.
SOURCE: ALR Technologies Inc.
I agree and it is needed. It would have never come to fruition if it was not needed. Again everyone needs to think globally not locally. Social medicine is over run and needs innovative solution for chronic care. Sydney is an inventor engineer and after much study with medical professionals designed a needed tool. This is heading down the run way and just ramping up
I sent Sidney a email to ask him the question if that was in the video and PR or if he was talking about something we don't know yet. I thought they covered this just earlier. I am at work so can't double check to be sure
If I am not mistaken that was in video 6 I believe
For everyone that is focused on the US market do you realize North America is less than 10% of the worldwide market? For those that are interested in the US market do you realize California is the first state where Pharmacist can prescribe diabetes meds? Has anyone researched what regions they are connected with around the world either via studies, filings, older PR'S and such.
Here is a clue. Go to alrt.com. Go to About ALRT and click leadership. Sidney is a engineer and finance guy. They have very strong ties to Canada and South America. Columbia and Chille and US. Sidney has strong ties to Asia. They have done studies in Kansas City. You have to go back at least as far as 2014 to see how this has all developed. Read all the PR'S on the site dating back. Read all the filings out.
How did they get on Fox News? Listen to the interview with then president Bill Smith.
This is not a company just popping up. IMO your going to see a very clear strategy in place soon. The FDA clearance was the juice they needed to get this rolling at a very fast pace. OTC is not for the patient. Here you just have to show patience. It would not keep bouncing back if this was lost. This company is going to have a high valuation if my research proves to be correct. They are going to prove the market next. That is next step before total commercial rollout
When I say patience I mean we will see things in a month and through Q1 IMO. He releases real news. I am following his years of work until I see a red flag. They did not get clearance to sit dormant. They are not getting filings updated to sit dormant. Just connect the dots
Correct he gives the company a line of credit
Don't know how many times it has to be said you will not hear anything unless it is needed. Sidney has and continues to personally fianance company. If you have questions just email him
US is not the primary target right now
Well said and this is not far off. They would not be getting current if there was nothing in the wirks
Major accumulation happening in mid 3's
Markets are forward looking. They have a ton of things going on they can report IMO. Sidney has said there will be news just not every day or other day. I would rather the news have an impact than just releasing PR'S for the sake of them
I will ask
I will ask
Are you new?
I just posted numbers from TA Friday there is no dilution. Get your facts straight
97.5% is owned by Sidney and his wife and couple others. He has been personally funding the company. 2.5% or 88M is the public float. This is why it moves so easily and is volatile. Sidney and wife have 20M invested. There is a potential for a PP but for now Sidney just continuing to finance the company until we see otherwise. In January 2016 I believe they downsized the company to put all available resources to get FDA clearance. There has been no dilution as the share structure has not changed since I have been following it when they got clearance. With the minority ownership so low this could easily see big spikes with the right news as Sidney is not selling. The share structure is set up to prevent any hostile takeover.
They are very close to some major developments happening now as far as being able to understand how they will monetize this product. All you have to do is read between the lines on the steps they are taking. I would recommend watching the videos very closely. Understanding reimbursements in social medicine. Understand data on meds that could be collected and the value that would have to big pharma. A understanding on how this could elevate diabetes care on a very large scale.
Possible news would be patent award. Who they may co market with. Any additional studies with the initial roll out. Changes in law in the US on who can prescribe the diabetes meds. California has already changed laws and Oregon has to some degree. In Canada pharmacists can prescribe as well as Dr's. This platform is going to be very disruptive but I believe the right big players will see enough benefit to do the heavy lifting to push for major adoption in geographies outside of the US. Who are those big players? When it comes to social medicine the biggest player of all is the government.
No change to Share structure as of 11/3
Good Afternoon. There appears to be no change. The share structure for 11/3/17 is below.
Authorized: 2,000,000,000
Issued: 242,777,909
Restricted: 152,776,740
Have a good day.
Johnnie
Johnnie Zarecor
Pacific Stock Transfer Company
Direct: 571-485-9999
Global Operations Center Capital Transfer Agency
6725 Via Austi Pkwy, Suite 300 121 Richmond St. W. Ste 401
Las Vegas, Nevada 89119 Toronto, ON M5H 2K1
Telephone: 571-485-9999 Telephone: 416-350-5007
Visit Our New Pacific Services Group Website Today!
PSG Logo
Or maybe not downtick
Not worried lots of news coming
Volume like this is usually a pre cursor to something good happening on fridays. At least that has been the trend.
As for PP just email Sidney.
Response from Ben
Thanks again.
Its in the sequence.
The BANJ shares are reversed first, then new shares are issued. The way it is expressed is confusing. A result of an extended negotiation and the way the negotiation was approached. In fact there is no expansion of capital at the current price before the reverse and issue of shares.
I hope this clarifies.
Ben Macpherson
CEO
Banjo & Matilda
Los Angeles | Sydney
I followed up to confirm 25-1 on the BANJ side and that is confirmed. Anyway you slice this it appears to come out with a very low float and .40 a share meaning MM's are stealing shares at a big discount right now.
Sent will report back.
As for Spectrum via their FB I don't trust that. Did the answer come from a principle in the company? Sounds odd.
Explain the exact question you want asked and I will email him again for a further explanation.
I think the next couple PR'S will WOW us. Just to much going on with getting current and rollout strategy. Sidney only releases ready news that is done. Very excited to see what the next part of the strategy is. Low float. 2.5 percent minority ownership. This ticker is going to rock with patience.
All I can tell you is what I got. I asked a very specific question on if the RS was on the public or private side and Ben's email is pretty clear. How the share structure looks post merge I suspect will be very very tight
I assume 25-1 which makes the valuation at .016 or greater today to get to .40. Post reverse I expect it to spike as well as the fundamentals and revenue in this low float will drive it
ANYONE SELLING BELOW .015 WAKE UP
Apologies for the delay.
The MOU is a little confusing. However the split occurs on the public side. Based on the valuation of the incoming business, the number of shares issued to the incoming business/acquisition, the effective valuation on the current shares is $0.015 or greater. The reverse split will take these to $0.40 per share. The split will occur at the same time as the acquisition completes.
I hope this clarifies.
Ben Macpherson
CEO
Banjo & Matilda
Los Angeles | Sydney
I am just being patient. This is pretty stable with no dilution. This will spike in news and there are some significant events happening IMO. They are not getting current just because
Very strong support
This stock is going to shock the world in November. MM's just playing reverse merger games getting cheap shares on zero volume. They will drop it on any sell. Once any news breaks this will explode as details emerge especially with low float. Right now we are seeing downside volatility but I gurantee MM's not selling back cheap on buys it will be walked right up quickly
It does not appear to me to be so sophisticated that a lot of training for a medical professional is needed. Pretty much plug, play and receive the data on the medical professional side. They have made this as simple as possible and got it down to one number. Seems pretty simple with the output AC1 predictor. They have the device, data and algorithm to produce the output to be evaluated as I see it
I would recommend you email Sidney. sidney.chan@arlt.com
He has a plan to monetize this platform to get the value out of it. I think there is much more going on behind the scenes than we are aware of or that people have really speculated on. It is all speculation at this point but to your point adoption is the key. What steps they are taking to get adoption is the question. I could speculate all day long on a couple different directions they could go but I am not a expert is social medicine . I only know enough from what I have read and pieced together.
A. Regular testing creates revenue from Big Pharma as more products are used
B. Regular testing is good for cost containment of the chronic disease before it gets to the next level. Benefits government in social health
Reimbursements play a role.
As for adoption I see two very big players that it would benefit in dollars and cents.. I think that is where the heavy lifting to promote adoption will come from in my opinion. It will not be all ALRT. Not to mention who they may partner with to co market
Most definitely a disruptive technology but a huge market for a patent protected platform if it is adopted. So to circle back around this is the wager we are placing. Is it solid enough?
this thing is so thin anyone wanting to exit right now will take it down. It will pop right back up as well not worried on this one
First IMO this is not a Dr play or even a USA play right now. It will be though eventually after rollout in other geographies
2nd it will not take the place of Dr follow ups
3rd quicker changes and adhearance to the care plan is a benefit for all
4th In Canada Pharmacist prescribe these meds for diabetes. IMO this is a pharmacy and Pharmacist play. This puts the drug maintenance and monitoring for this chronic disease right where thy pick up meds. They will see their Dr as needed I would imagine.
5th laws for Pharmacist in the US are changing to also be able to prescribe.
6th this is a global play so we have to thinks in terms of social medicine and reimbursements. I had a hard time getting out of USA mode but once you do it is easier to see what avenue this may take.
ALRT has Canadian, US and South American along with Asian connections. Think of global medicine not USA medicine IMO. Just google Canada diabetes and start poking around to see how it all works. Once you understand they give patients X amount of dollars for maintenance and supplies this platform makes total sense
This is from Sidney
The ALRT System is designed to do 2 things:
1. Make it easy for patients to understand how they are doing. Simply by sending the patients their A1C target with the latest Predictive A1C is a simple and easily understood way to let the patients know how they are doing.
2. A1C to Advance Therapy was put in place after we looked at the 2 published papers, as shown in the Problems with Diabetes Care video, on failure of Healthcare Providers to advance therapy on a timely basis.
There is a lot of good news in the pipeline. Just read between the lines
.15-.20 based on current stage of development and not far from the first commercial rollout
Higher as it developes.
News to come out
Who they will co market with
Filings to get up to date. We will be able to see his personal investment and how Sidney has funded the company. It will explain why this is so thin
News on commercial rollout. When and strategy
The money will not be made in the medical device. The money will be made on the fees to utilize the AC1 predictor software
I have done a ton of studying on this. I think .15-.20 would be a fair target today
They have been very active on twitter with how the A1C predictor will work with each drug. This platform is gong to collect a lot of data and I imagine that data is valuable to big pharma not to mention all the other benefits that have been talked about.
I am pretty sure each drug manufacturer is watching their development. Each drug listed in the last PR would have also been notified they were in a PR. Very good way for those Pharma to start reviewing what they have. I think that is what we are seeing the last two days
Thanks! Sent him a question.